Cardiol Therapeutics: A Leader in Research and Commercial Development of Pharmaceutical Cannabidiol Products and Targeted Therapies for Heart Failure and Cancer Pharmaceutical Investing
Cardiol Therapeutics Completes Initial Public Offering and the Company’s Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols “CRDL” and “CRDL.WT” Cannabis Investing News
Collaboration with Major European Lateral Flow Test Developer and Sona Nanotech Inc. Nanotech Investing
California Nanotechnologies Announces Positive Cash Flow for Q2/F2019 & New SPS Contract Nanotech Investing
